Tyrosine kinase inhibitorFDA-approvedFirst-line
Trametinib
How it works
Blocks MEK1 and MEK2 in cancer cells, preventing uncontrolled growth.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 4.8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Trametinib for Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Trametinib Shows Promise for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | The median progression-free survival was 20.1 months in patients with high tumor pERK expression versus 5.6 months with standard-of-care treatment. | Source → |
| New Insights into Treating Low-Grade Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Comparing Treatments for Melanoma Patients | Melanoma | meta-analysis | Dabrafenib and trametinib improved recurrence-free survival (RFS) compared to anti-PD(L)1 therapies (hazard ratio [HR] 0.53, 95% CI, 0.40-0.70, P < .01). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.